ClinicalTrials.gg
Status unknownNCT03450421Updated Mar 1, 2018

Safety and Efficacy of Actamax™Adhesion Barrier in Women Undergoing Laparoscopic Abdominopelvic Surgery/Myomectomy

An interventional study of Actamax™Adhesion Barrier in Uterine Fibroid, sponsored by Actamax Surgical Materials LLC. Status unknown. Open to female participants aged 18 Years to 44 Years. Per ClinicalTrials.gov, last updated 2018-03-01.

Sponsored by Actamax Surgical Materials LLC · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Feb 2018), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
152
Allocation
Randomized
Ages
18 Years to 44 Years
Sex
Female
01

Study summary

Women undergoing laparoscopic abdominopelvic surgery with a planned, second look laparoscopy within 8-12 (+4) weeks will be enrolled. All subjects must undergo myomectomy with/without treatment of co-existing pathology e.g. (+/-) adhesions and/or (+/-) endometriosis, and/or (+/-) adenomyosis, and/or (+/-) ovarian cyst(s). The value of the second look laparoscopy (SLL) must be confirmed by the investigator to be of clinical benefit to the subject. The subject must be desirous of future fertility and willing to undergo the SLL to assess whether pathology (e.g. adnexal adhesions or endometriosis) exists which could be treated with a goal of improving their likelihood of conceiving and progressing to full term.

02

Conditions studied

  • Uterine Fibroid

Browse trials for

03

In context

Leiomyoma

496 studies on the registry are indexed under Leiomyoma; 79 are open to participants now.

This study's planned enrollment of 152 is above the median of 62 across 350 interventional studies indexed under Leiomyoma.

Browse Leiomyoma studies →

Lead sponsor

Actamax Surgical Materials LLC is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 44 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Preoperative Inclusion Criteria:

  • Understand and be able to follow the requirements of the protocol including personally signing and dating an IRB approved Informed Consent Form prior to undergoing any protocol related procedures,
  • Be a premenopausal female, > 18 and \< 44 years old,
  • Be thought to have uterine fibroids requiring laparoscopic abdominopelvic surgery that will require a > 3 cm posterior uterine incision (including repeat myomectomy/previous uterine artery embolization for fibroid), and/or +/- adhesions, and/or +/- endometriosis, and/or +/- adenomyosis and/or ovarian cyst(s),
  • Wish to retain her fertility and be considered to clinically benefit from a SLL, in the investigator's opinion,
  • Have a willingness to undergo a second look laparoscopy if surgeon considers it clinically beneficial to the subject,
  • Have a negative pregnancy test within 5 days of surgery,
  • Agree to avoid pregnancy using adequate forms of contraception (oral contraceptive pill, condom, no sexual intercourse), and is aware and agrees to avoid pregnancy for a minimum of 12 weeks or to SLL (whichever is greater) to allow for healing of the uterine scar following myomectomy,
  • Is willing, able and likely to fully comply with study procedures and restrictions including follow-up,
  • Be in good health including an ASA (American Society of Anesthesiologists) score of 2 or less,
  • Have undergone a satisfactory physical and medical assessment with no clinically significant and relevant abnormalities.

Intraoperative Inclusion Criteria:

  • The subject underwent a laparoscopic myomectomy with at least (1) posterior uterine serosal incision of > 3 cm in length,
  • The subject meets all intraoperative inclusion/exclusion criteria prior to randomization,

And

  • At the completion of the procedure, before randomization, the surgeon believes that the subject will clinically benefit from a second look laparoscopy to preserve fertility.

Preoperative Exclusion Criteria:

  • Are unable to give their own written informed consent,
  • Have completed her family planning with no desire to maintain fertility,
  • Are considered to have no potential clinical benefit from a second look laparoscopy,
  • Are currently pregnant (including ectopic pregnancy),
  • Are breastfeeding,
  • Are within 6 weeks post-partum,
  • Have received or are expected to receive another anti-adhesive treatment within 30 days prior to enrollment or during enrollment up to adhesion evaluation at second look laparoscopy,
  • Are currently or have been enrolled within the last 30 days in another interventional study.
  • Have received or are expected to receive any other investigational product or technique within 30 days prior to or during enrollment,
  • Have had cancer within 5 years of the initial surgery with the exception of basal cell carcinoma,
  • Have known allergy to dextran, PEG, or FD\&C Blue #1,
  • Have had bilateral salpingectomy,
  • Have had a hysterectomy,
  • Are scheduled to undergo concomitant non-gynecologic surgery,
  • Have pre-operative imaging results with:
  • Largest fibroid diameter \< 2 cm, or
  • Largest intramural fibroid diameter >10 cm, or
  • More than 5 intramural fibroids with a diameter of > 8 cm, and/or
  • Adenomyoma >10 cm.
  • Have a history where it is expected that complete adhesiolysis will be impossible,
  • Have clinically significant abnormal blood results,
  • Have clinically relevant hemochromatosis, hepatic, renal, autoimmune, lymphatic, hematological or coagulation disorders,
  • Have insulin dependent diabetes mellitus,
  • Are receiving concurrent systemic corticosteroids, antineoplastic agents and/or radiation therapy,
  • Have had previous abdominal or pelvic radiation therapy,
  • Have active pelvic or abdominal infection, or other active infection with fever >100°F/38°C,
  • Have a known history of methicillin-resistant Staphylococcus aureus (MRSA), HIV, HBV or HCV.

Intraoperative Exclusion Criteria:

  • Have cancer detected at surgery,
  • Are pregnant, including ectopic pregnancy,
  • Have a non-gynecologic surgical procedure or entry into the bowel, bladder, or ureter,
  • Have a hysterectomy or other gynecologic procedure that would render the subject unable to conceive,
  • Have incomplete lysis of any pre-existing pathological adhesions,
  • Have extensive enterolysis,
  • Have incomplete surgical treatment of endometriosis,
  • Receive the administration of a product that will interfere with the application of Actamax™ Adhesion Barrier,
  • Receive the use of an approved or unapproved product or strategy for the purpose of preventing adhesion development,
  • Receive fibrin glue, surgical sealant, or other hemostatic agent,
  • Undergo an open procedure (other than mini laparotomy to remove fibroids),
  • Undergo a posterior colpotomy,
  • Undergo insufflation with a gas other than CO2,
  • Undergo Laprolift or similar device for elevation of the abdominal wall, as an alternative to CO2 insufflation,
  • Undergo abdominal cavity heating, humidification or oxygenation,
  • Receive irrigants containing, glucocorticoids, antihistamines, heparin or antiseptic additives,
  • Have any instillates left at the end of surgery,
  • Have a postoperative drain,
  • Undergo laparoscopic myomectomy without at least one posterior uterine serosal incision of > 3 cm in length,
  • Undergo a diagnostic hysteroscopy or polypectomy or therapeutic hysteroscopy which includes any of the following:

    1. Undertaken during or following the laparoscopic myomectomy,
    2. Treatment of fibroids >3 cm,
    3. Solution other than Lactated Ringer's Solution (LRS) used for uterine distention,
    4. Laparoscopic filming commenced after removal of LRS.
  • If, in the opinion of the surgeon, subject would have no clinical benefit for a SLL.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
152 participants (estimated)

Study arms

  • Experimental
    Actamax™Adhesion Barrier

    Following Myomectomy, subjects randomized to the Actamax™Adhesion Barrier Arm will have up to 30mL of product applied to all sites of surgery (area of treatment/trauma).

    Device: Actamax™Adhesion Barrier

  • No intervention
    Surgical Control

    Myomectomy will be performed with no adhesion barrier application.

Interventions

  • DeviceActamax™Adhesion Barrier

    Actamax™Adhesion Barrier is a degradable hydrogel to be sprayed directly on surgically traumatized tissue. The aim of using the Actamax™ Adhesion Barrier (AB) in this way is to allow damaged and apposing tissue surfaces the opportunity to heal separately without becoming abnormally attached.

06

What researchers measure

Primary outcomes

  1. Adhesion Free at Sites of Surgery at SLL

    The primary efficacy outcome measure will be being adhesion free at sites of surgery throughout the whole abdominopelvic cavity at SLL.

    Time frame: 8-12 weeks postoperatively but out to 16 weeks where circumstances require (vacations, etc.)

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 1, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03450421
Lead sponsor
Actamax Surgical Materials LLC
Responsible party
Sponsor
First posted
Mar 1, 2018
Start date
Jun 2018 (estimated)
Primary completion
Nov 2019 (estimated)
Completion
Jul 2024 (estimated)
Last update
Mar 1, 2018

Study contacts

Trudy D Estridge, PhD
Contact
trudy.estridge@actamax.com
650-245-6561
Trudy Estridge
study director · Actamax Surgical Materials LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion